Efficacy and safety of PARP inhibitor monotherapy and combination regimens for advanced or recurrent endometrial cancer:a network meta-analysis
- VernacularTitle:PARP抑制剂单药及联合方案治疗晚期或复发性子宫内膜癌有效性与安全性的网状Meta分析
- Author:
Zi LIANG
1
;
Tianqi LIU
1
;
Ruixue LI
2
;
Zinan ZHAO
3
;
Wenfeng XU
3
;
Pengfei JIN
3
Author Information
1. Dept.of Pharmacy,Beijing Hospital,National Center of Gerontology/National Clinical Research Center for Gerontology/The Key Laboratory of Geriatrics of NHC/Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Dept. of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China
2. Dept.of Pharmacy,Beijing Hospital,National Center of Gerontology/National Clinical Research Center for Gerontology/The Key Laboratory of Geriatrics of NHC/Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Dept. of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;Dept. of Pharmacy,People’s Hospital of Xizang Autonomous Region,Lhasa 850000,China
3. Dept.of Pharmacy,Beijing Hospital,National Center of Gerontology/National Clinical Research Center for Gerontology/The Key Laboratory of Geriatrics of NHC/Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China
- Publication Type:Journal Article
- Keywords:
endometrial cancer;
poly(ADP-ribose) polymerase inhibitor;
Advanced;
Recurrent;
Efficacy;
Safety
- From:
China Pharmacy
2026;37(21):2873-2879
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the efficacy and safety of poly(ADP-ribose) polymerase inhibitor (PARPi) monotherapy and its different combination regimens in the treatment of advanced or recurrent endometrial cancer.METHODS PubMed, Embase, The Cochrane Library, Web of Science, CNKI, and Wanfang Data were searched to identify randomized controlled trials (RCT) of PARPi monotherapy, PARPi+immune checkpoint inhibitor (ICI), and PARPi+anti-angiogenic agent (AA), as well as RCT providing direct or indirect comparative evidence for the above regimens, including ICI monotherapy, AA monotherapy, ICI+AA, and conventional chemotherapy. The search period was from database inception to March 10, 2026. After literature screening, data extraction, and quality assessment, a network meta-analysis was performed using Stata 18.0 and R 4.5.2.RESULTS A total of 12 studies were included,involving 5 059 patients. There was no statistically significant difference in progression free survival (PFS) among patients treated with PARPi monotherapy, PARPi+ICI, and PARPi+AA ( P >0.05).Compared with conventional chemotherapy, ICI monotherapy, PARPi+ICI, PARPi+AA, and ICI+AA significantly prolonged PFS ( P <0.05). According to surface under the cumulative ranking curve (SUCRA), the ranking was PARPi+AA>AA monotherapy>PARPi+ICI>ICI+AA>PARPi monotherapy>ICI monotherapy>conventional chemotherapy. There were no statistically significant difference in objective response rate among the interventions ( P >0.05);the SUCRA ranking was ICI+AA>PARPi+AA>ICI monotherapy>AA monotherapy>conventional chemotherapy>PARPi monotherapy. Compared with PARPi+ICI and PARPi monotherapy, the incidence of grade ≥3 adverse events was significantly higher in patients receiving PARPi+AA ( P <0.05);the SUCRA ranking was conventional chemotherapy>ICI monotherapy>PARPi+ICI>ICI+AA>PARPi monotherapy>AA monotherapy>PARPi+AA.CONCLUSIONS PARPi+ICI and PARPi+AA showed certain PFS benefits in patients with advanced or recurrent endometrial cancer, while PARPi+ICI had a more favorable safety profile.